<DOC>
	<DOCNO>NCT02562807</DOCNO>
	<brief_summary>The purpose study evaluate pharmacological effect , safety pharmacokinetic TAS-303 female patient Stress Urinary Incontinence .</brief_summary>
	<brief_title>A Study TAS-303 Female Patients With Stress Urinary Incontinence</brief_title>
	<detailed_description>This study double-blind , placebo-controlled crossover study . The main purpose study evaluate Urethral Pressure Profile Parameters Stress Urinary Incontinence patient receive single dose TAS-303 Placebo .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Key Patient symptom Stress Urinary Incontinence ( SUI ) least 12 week prior study entry Patient weight least 45 kg body mass index ( BMI ) range 18.030.0 kg/m2 , inclusive , screen Patient positive 1hour pad weight test screen Patient least 2 incontinence episode per week . Key Patient predominant primary urge incontinence accord investigator judgment Patient prior surgical SUI treatment Patient diagnose Pelvic Organ Prolapse Patient currently take medication , take medication last 4 week , urinary incontinence effect urinary output function include anticholinergic antihistamine antianxiety medication . Patient positive pregnancy test</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Urinary Incontinence , Stress</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
</DOC>